MARKET

MRUS

MRUS

Merus
NASDAQ
55.29
+0.48
+0.88%
Closed 18:00 07/19 EDT
OPEN
54.91
PREV CLOSE
54.81
HIGH
56.58
LOW
54.46
VOLUME
518.19K
TURNOVER
0
52 WEEK HIGH
61.61
52 WEEK LOW
19.81
MARKET CAP
3.72B
P/E (TTM)
-20.3003
1D
5D
1M
3M
1Y
5Y
1D
TimesSquare Capital U.S. Small Cap Growth Q2 2024 Commentary
Seeking Alpha · 07/15 15:10
Weekly Report: what happened at MRUS last week (0708-0712)?
Weekly Report · 07/15 11:34
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Biotech indexes lagged broader market indexes in the first half of 2024. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and the Fed is expected to cut rates in September. The second half of 2024 holds potential for biotech stocks to break out of their consolidation.
Seeking Alpha · 07/09 11:00
Buy Rating Affirmed for Merus’s Petosemtamab on Promising mCRC and HNSCC Trial Prospects
TipRanks · 07/09 10:55
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
NASDAQ · 07/08 13:08
Weekly Report: what happened at MRUS last week (0701-0705)?
Weekly Report · 07/08 11:36
Analyst Maintains Buy Rating on MRUS Amidst C-Suite Restructuring and Strategic Growth Initiatives
Leerink Partners analyst Andrew Berens has maintained their bullish stance on Merus stock, giving a Buy rating on July 2. Berens believes the recent C-suite changes at Merus US are a strategic move as the company prepares for its next phase of growth. MRUS’s price has also increased 98.00% in the past six months.
TipRanks · 07/04 05:35
Merus: Initial statement of beneficial ownership of securities
Press release · 07/03 22:35
More
About MRUS
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Webull offers Merus NV stock information, including NASDAQ: MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRUS stock methods without spending real money on the virtual paper trading platform.